Bruce Rashbaum

1.1k total citations
9 papers, 384 citations indexed

About

Bruce Rashbaum is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Bruce Rashbaum has authored 9 papers receiving a total of 384 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 8 papers in Virology and 3 papers in Emergency Medicine. Recurrent topics in Bruce Rashbaum's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (8 papers) and HIV/AIDS Research and Interventions (6 papers). Bruce Rashbaum is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (8 papers) and HIV/AIDS Research and Interventions (6 papers). Bruce Rashbaum collaborates with scholars based in United States, Germany and United Kingdom. Bruce Rashbaum's co-authors include Andrew Cheng, Jeffrey L. Stephens, Richard Elion, Amanda Clarke, Nathan Clumeck, Marshall W. Fordyce, José Ramón Arribas, Pablo Tebas, Paul E. Sax and S. Ramanathan and has published in prestigious journals such as SHILAP Revista de lepidopterología, AIDS and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Bruce Rashbaum

9 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruce Rashbaum United States	6	340	235	137	68	29	9	384
David Shamblaw United States	6	341 1.0×	239 1.0×	143 1.0×	48 0.7×	24 0.8×	7	379
Awny Farajallah United States	8	599 1.8×	408 1.7×	243 1.8×	85 1.3×	19 0.7×	12	649
Antonio Antela Spain	8	300 0.9×	214 0.9×	98 0.7×	57 0.8×	12 0.4×	22	353
Gianmaria Baldin Italy	13	387 1.1×	294 1.3×	124 0.9×	84 1.2×	27 0.9×	50	457
Elisabetta Chiesa Italy	11	306 0.9×	242 1.0×	96 0.7×	63 0.9×	14 0.5×	17	351
Michael Giordano United States	6	502 1.5×	389 1.7×	292 2.1×	48 0.7×	22 0.8×	10	582
Anita Scribner United States	6	203 0.6×	156 0.7×	62 0.5×	48 0.7×	12 0.4×	7	245
Stephan Klauke Germany	10	252 0.7×	201 0.9×	90 0.7×	75 1.1×	49 1.7×	24	332
Eugénio Teófilo Portugal	9	254 0.7×	178 0.8×	63 0.5×	74 1.1×	12 0.4×	22	319
Margherita Bracchi United Kingdom	7	187 0.6×	126 0.5×	75 0.5×	98 1.4×	29 1.0×	25	268

Countries citing papers authored by Bruce Rashbaum

Since Specialization

Citations

This map shows the geographic impact of Bruce Rashbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Rashbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Rashbaum more than expected).

Fields of papers citing papers by Bruce Rashbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Rashbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Rashbaum. The network helps show where Bruce Rashbaum may publish in the future.

Co-authorship network of co-authors of Bruce Rashbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Rashbaum. A scholar is included among the top collaborators of Bruce Rashbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Rashbaum. Bruce Rashbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Rashbaum, Bruce, Christoph D. Spinner, Cheryl McDonald, et al.. (2019). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study. SHILAP Revista de lepidopterología. 20(1). 24–33. 4 indexed citations

Orkin, Chloe, Anthony Mills, Cynthia Brinson, et al.. (2018). Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials. HIV Medicine. 19(10). 724–733. 42 indexed citations

Spinner, Christoph D., Bruce Rashbaum, Cheryl McDonald, et al.. (2018). 541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging. Open Forum Infectious Diseases. 5(suppl_1). S201–S201. 1 indexed citations

Wohl, David A., Shinichi Oka, Nathan Clumeck, et al.. (2016). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. 72(1). 58–64. 145 indexed citations

Mills, Anthony, Gordon Crofoot, Roberto Ortiz, et al.. (2014). Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data. HIV Clinical Trials. 15(2). 51–56. 17 indexed citations

Cohen, Calvin, Richard Elion, Peter Ruane, et al.. (2011). Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 25(6). F7–F12. 93 indexed citations

Skiest, Daniel J., Calvin Cohen, Karam Mounzer, et al.. (2011). Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients. HIV Clinical Trials. 12(3). 131–140. 5 indexed citations

Lori, Franco, Richard B. Pollard, Lucia Whitman, et al.. (2005). Lowering the Dose of Hydroxyurea Minimizes Toxicity and Maximizes Anti-HIV Potency. AIDS Research and Human Retroviruses. 21(4). 263–272. 9 indexed citations

Eron, Joseph J., Robert L. Murphy, Dolores M. Peterson, et al.. (2000). A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)*. AIDS. 14(11). 1601–1610. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact